NOVEMBER 2022LIFE SCIENCES REVIEW 19The future will revolve around advanced biologics, cell and gene therapy. We want to establish a leadership position in this field and become a go-to resource that helps companies bring innovative medicines to market and benefit patientnovel investigational T-cell therapy platform. In another instance, it counseled a mid-sized biotech company on commercial restructuring initiatives during COVID-19 that led to higher HCP engagement and delivered P&L impact. The Comprehensive 360 Launch Accelerator ProgramBoulder Biotech Launch Specialists works with clients through its proprietary 360 Launch Accelerator program, performing a 30-day Launch Readiness Diagnostic. It then recommends one of the four core pillars of its offerings: 360 Commercial Launch Accelerator, 360 Clinical Operations Launch Accelerator, 360 Operational Launch Readiness Accelerator, or 360 Cell Therapy Launch Readiness Accelerator. Boulder Biotech Launch Specialists goes above and beyond as a marketing strategy consulting firm. The advisors come with extensive industry launch experience. This is a massive value proposition, given that hiring field teams and working on marketing and market access is an afterthought for most biotech companies. Boulder Biotech Launch Specialists renders its services via the traditional project-based contract or a flexible subscription-based approach. In the latter, for a flat monthly fee, the company deploys virtual or on-site resources to add functional area expertise early--before commercial teams and FTEs are hired--in clinical development. It can also dispatch contract employees to help clients fill capability gaps and assist them with building marketing and launch infrastructure. In the wake of the U.S. biotech scene rapidly evolving and diversifying, companies like Boulder Biotech Launch Specialists are indispensable partners for established and emerging biotech entities. Enabling biotech companies to do what they do best, it ensures the story and value of their initiatives get the recognition and resonance they deserve. After all, the patient wins when a product is launched optimally and when providers have access to novel therapeutics."The future will revolve around advanced biologics, cell and gene therapy. We want to establish a leadership position in this field and become a go-to resource that helps companies bring innovative medicines to market and benefit patients," adds Leidli.Leidli has also launched a podcast, Rx for Biotech, to take a deep dive into the biotech ecosystem. Industry leaders and disruptors share their insights and knowledge to inform biotech companies regarding the intricacies of cell and gene therapy and the importance of organizational launch readiness. The podcast holds immense importance for more than 650 cell and gene therapy developers in the U.S., and many new approvals that are expected over the next decade.
< Page 9 | Page 11 >